Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Urologic oncology

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2011.08.009PMID 21956045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

  2011influential reference
• Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

  2011cited by this paper
• Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience.

  2011cited by this paper
• Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients

  2010cited by this paper
• Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.

  2010cited by this paper
• Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.

  2010cited by this paper
• Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma.

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

  2008cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.

  2005cited by this paper
• Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

  2005influential reference
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper
• Albumin as an aid to the interpretation of serum calcium.

  1971cited by this paper

• Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients

  2024cites this paper
• Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma.

  2021cites this paper
• The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma

  2021cites this paper
• Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis.

  2020cites this paper
• Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma.

  2019cites this paper
• Current status of prognostic factors in patients with metastatic renal cell carcinoma

  2019cites this paper
• Prognostic role of corrected calcium levels in renal cell carcinoma : a systematic review and meta-analysis

  2018cites this paper
• Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan

  2018cites this paper
• Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

  2016cites this paper
• Prognostic Role of Lactate Dehydrogenase Expression in Urologic Cancers: A Systematic Review and Meta-Analysis

  2016cites this paper
• Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma

  2015cites this paper
• Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

  2015cites this paper
• Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

  2015cites this paper
• C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review

  2015cites this paper
• Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis

  2015cites this paper
• Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy

  2015cites this paper
• Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis

  2015influential citation
• The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.

  2014cites this paper
• Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment

  2014cites this paper
• Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice

  2013cites this paper
• Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma

  2013cites this paper
• A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma

  2012cites this paper